Literature DB >> 9072839

[Preradiotherapy chemotherapy in primary CNS lymphomas: progress?].

N Schwegler.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9072839     DOI: 10.1007/bf03038931

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  5 in total

1.  Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315.

Authors:  D F Nelson; K L Martz; H Bonner; J S Nelson; J Newall; H D Kerman; J W Thomson; K J Murray
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

2.  [Primary cerebral non-Hodgkin's lymphomas. The results of radiotherapy].

Authors:  M Hetzel-Sesterheim; K Schnabel; U Nestle; G Hamann; W Berberich
Journal:  Strahlenther Onkol       Date:  1996-04       Impact factor: 3.621

3.  [Radiotherapy of malignant lymphomas of the brain: Radiologic behavior in relation to radiation dose and volume].

Authors:  M Notter; N Schwegler
Journal:  Strahlenther Onkol       Date:  1995-12       Impact factor: 3.621

4.  Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06.

Authors:  C Schultz; C Scott; W Sherman; B Donahue; J Fields; K Murray; B Fisher; R Abrams; J Meis-Kindblom
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544

5.  Improved survival rate in primary intracranial lymphoma treated by high-dose radiation and systemic vincristine-doxorubicin-cyclophosphamide-prednisolone chemotherapy.

Authors:  Y Shibamoto; K Tsutsui; Y Dodo; H Yamabe; N Shima; M Abe
Journal:  Cancer       Date:  1990-05-01       Impact factor: 6.860

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.